BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191118
DTEND;VALUE=DATE:20191121
DTSTAMP:20260515T032619
CREATED:20180531T073809Z
LAST-MODIFIED:20190605T115541Z
UID:16039-1574035200-1574294399@www.pharmajournalist.com
SUMMARY:Ophthalmic Drugs
DESCRIPTION:SMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day\, taking place on the 18th-20th November 2019 in London\, UK. \n \nThe global ophthalmic drug market size is expected to reach a value of $30 billion USD by 2023 with growing focus on alternative delivery approaches to replace intravitreal drug delivery and novel drug development being the key factors driving the market. \nWith this in mind\, this year’s Ophthalmic Drugs conference will explore new discoveries in the treatment of ocular rare disease; innovations in gene therapy; the challenges in drug delivery through a complex barrier; patient comfort and regulatory compliance which make up  core components within the Ophthalmic Drug sphere. \nNEW FOR 2019: \nThe brand-new Focus Day on ‘Novel Drug Delivery Through a Complex Barrier’ will bring academic perspectives on the future for ocular drug delivery and notified bodies will provide a regulatory insight into this emerging field of ophthalmic drug development. \nHow will you benefit? \nWith over 15 expert presentations\, the three-day agenda offers you peer-to-peer networking with Global Product Managers\, Heads of Drug Development\, Senior Directors of Ophthalmology\, Heads of Research and Development and many more! \nNetwork and learn from leading professionals such as: \nCHAIRS FOR 2019: \n\nMitchell de Long\, Vice President\, Chemistry\, Aerie Pharmaceuticals\nNaj Sharif\, Vice President\, Global Ophthalmology\, Santen Inc\, USA\n\nFEATURED SPEAKERS INCLUDE: \n\nParisa Zamiri\, Global Head of Clinical Development in Ophthalmology\, Novartis Pharmaceutical Inc.\nGavin Spencer\, Executive Vice President and Chief Business Officer\, Nicox\nAniz Girach\, Chief Medical Officer\, ProQR Therapeutics\nDaniel Chung\, Global Medical Strategy Lead- Ophthalmology\, Spark Therapeutics\nMichael Ehrlich\, Senior Clinical Program Lead – Retinopathies\, Boehringer Ingelheim\nPeter Morgan-Warren\, Medical Assessor\, MHRA\nWilliam Dallman\, Clinical Development Manager\, Eyenuk\n\nFor more information and to register\, visit: www.ophthalmicdrugs.com/pj \nEarly-Bird Rates \n\nBOOK BY 28TH JUNE AND SAVE £300\nBOOK BY 30TH SEPTEMBER AND SAVE £100\n\nSocial Media Handles \nFollow us on LinkedIn ‘SMi Pharma’\, Twitter @SMiPharm and use #OphthalmicDrugs \nContact Info: \nT: +44 (0) 20 7827 6164\nE: nhoward@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/ophthalmic-drugs-2019/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191118
DTEND;VALUE=DATE:20191121
DTSTAMP:20260515T032619
CREATED:20180905T081807Z
LAST-MODIFIED:20190717T092148Z
UID:17493-1574035200-1574294399@www.pharmajournalist.com
SUMMARY:3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) 2019
DESCRIPTION:AFDD is back for its third year as the only conference to bring together industry leaders\, clinicians and academic experts focused on finding an effective anti-fibrotic treatment. \n \nOver 3 days packed with compelling case studies\, diverse panels and varied networking opportunities\, you’ll glean insights from industry and academic leaders across fibrotic disease areas. The 2019 agenda will reflect the strides taken by the community over the past year as well as forming the future of anti-fibrotic drug development. \nTo learn more about this event\, and to register online\, visit https://afdd-summit.com/ \nContact:\nPhone – (+1) 617 455 4188\nEmail – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/afdd-summit-2019/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191119
DTEND;VALUE=DATE:20191121
DTSTAMP:20260515T032619
CREATED:20190809T095122Z
LAST-MODIFIED:20190813T105926Z
UID:21871-1574121600-1574294399@www.pharmajournalist.com
SUMMARY:1st RNA Editing Summit 2019
DESCRIPTION:  \nTranslating Emerging RNA Editing Approaches for Therapeutic Applications. \nAs CRISPR genome editing struggles to overcome key specificity and delivery challenges in its pursuit to realize therapeutic applications\, the 1st RNA Editing Summit 2019 accelerates the translation and commercialization of RNA editing for an array of research and therapeutic applications. \nAs the therapeutic potential of RNA editing explodes\, discover the fundamental mechanisms of RNA editing\, such as recruiting endogenous ADARs with encodable guideRNAs\, and learn about the novel approaches being developed to precisely and efficiently deliver intended RNA edits. With the temporary nature of RNA editing providing a huge opportunity in many areas beyond genetic diseases\, uncover how to recruit endogenous editing enzymes and ultimately deliver safe and effective transcriptome edits. \nJoin RNA\, functional genomic\, cell biology and immuno-oncology experts from large pharma\, biotech and academia at the 1st RNA Editing Summit 2019 in the pursuit of translating emerging RNA editing mechanisms into therapeutic reality. \nTo learn more about this event\, and to register online\, visit https://ter.li/jikni6
URL:https://www.pharmajournalist.com/event/1st-rna-editing-summit-2019/
LOCATION:Revere Hotel Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191119
DTEND;VALUE=DATE:20191122
DTSTAMP:20260515T032619
CREATED:20190910T085210Z
LAST-MODIFIED:20190910T085210Z
UID:22357-1574121600-1574380799@www.pharmajournalist.com
SUMMARY:3rd Annual Dermatology Drug Development Summit
DESCRIPTION:The Dermatology Drug Development Summit series is a unique industry-focused forum dedicated to innovating\, accelerating and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs\, in the treatment of high unmet need. \nThe 3rd Annual Dermatology Drug Development Summit provides leading industry experts with a unique forum to debate the end-to-end challenges in dermatology drug development: from discovering new research on key disease pathways\, to unveiling critical preclinical insights\, discussing formulation strategies\, defining the optimal clinical development plans or evaluating commercialization approaches. \nJoin peers and leaders in this space for an exclusive three-day meeting of comprehensive discussion\, sharing of latest advances and pioneering insights\, and networking opportunities. \nHear from 30+ experts including: \n\nSonya Abraham\, Head of New Treatment Strategies\, Immunology\, UCB\nDavid Rubenstein\, CSO\, Dermavant Sciences\nKendall Marcus\, Director – Division of Dermatology & Dental Products\, FDA\nMichael Kuligowski\, Executive Medical Director – Inflammation & Autoimmunity\, Incyte Corporation\nJohn Harris\, Vice Chair of Dermatology & Director\, Vitiligo Clinic & research Center\, University of Massachusetts Medical School\nSuma Krishnan\, Founder & COO\, Krystal Biotech\n\nAcross an end-to-end\, comprehensive agenda\, learn from case studies on: \n\nHow to enhance preclinical activities\nThe latest advances in translational research\nHow to advance topical drug development and formulation approaches\nHow to accelerate clinical development and what are the latest clinical results\nHow to tackle the evolving regulatory and commercial landscape in dermatology\n\nFind out more here: https://ter.li/jj7wxg
URL:https://www.pharmajournalist.com/event/3rd-annual-dermatology-drug-development-summit/
LOCATION:Aloft Boston Seaport District\, Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191119
DTEND;VALUE=DATE:20191122
DTSTAMP:20260515T032619
CREATED:20190924T113636Z
LAST-MODIFIED:20190924T113636Z
UID:22548-1574121600-1574380799@www.pharmajournalist.com
SUMMARY:Gene Therapy Analytical Development
DESCRIPTION:The inaugural Gene Therapy Analytical Development Summit will unite large pharma and innovative biotechs to develop robust analytical tools to guarantee the consistency\, quality and safety of gene therapy products. \n \nFocused specifically on addressing the unique analytical challenges posed by gene therapy vectors\, this technical scientific meeting will unite the ‘boots on the ground’ scientists grappling with these challenges first-hand. \nDelving into technical analytics to assess potency\, capsid integrity\, empty vs full capsids and viral titers of AAV and lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. \nTo learn more and to register online\, visit https://ter.li/z1fc6v
URL:https://www.pharmajournalist.com/event/gene-therapy-analytical-development/
LOCATION:Renaissance Boston Waterfront Hotel 606 Congress Street Boston\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR